Abstracts tagged "autoantibodies"

Abstract Number: 282 • 2016 ACR/ARHP Annual Meeting
From ‘immune Mediated Necrotizing Myopathy’ to ‘antibody-Mediated Necrotizing Myositis: Towards the Pathogenic Role of Anti-SRP and Anti-Hmgcr Antibodies’
Yves Allenbach¹, Louiza Arouche-Delaperche², Corinna Preusse³, Gillian Butler Browne², Nicolas Champtiaux⁴, Kuberaka Mariampillai⁵, Aude Rigolet⁶, Peter Hufnagl⁷, Norman Zerbe⁸, Thierry Maisonobe⁹, Damien Amelin², Sarah Leonard-louis¹⁰, Charles Duyckaerts¹¹, Bruno Eymard¹², Hans-Hilmar Goebel³, Laurent Drouot¹³, Olivier Boyer¹⁴, Olivier Benveniste^2,5 and Werner Stenzel³, ¹Pitié-Salpêtrière University Hospital, AP-HP, Department of Internal Medicine and Clinical Immunology, Paris, France, Paris, France, ²Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ³Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ⁴Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁵Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ⁶Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁷Pathology departmen, Charite Hospital, Berlin, Germany, ⁸Department of Pathology, Charite Hospital, Berlin, Germany, ⁹Pitié-Salpêtrière University Hospital, AP-HP, Department of Neuropathology, Paris, France, Paris, France, ¹⁰Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Neuropathology, Paris, France, Paris, France, ¹¹Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ¹²Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ¹³Immunology, INSERM U905, University of Rouen, Rouen, France, ¹⁴Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Immune mediated necrotizing myopathy (IMNM) has been recently added as a new entity among dermatomyositis, polymyositis and sporadic inclusion body myositis. IMNM is defined…
Abstract Number: 1083 • 2016 ACR/ARHP Annual Meeting
Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Petra Budde¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Hans-Dieter Zucht¹, Heike Göhler¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In systemic lupus erythematosus (SLE), early diagnosis and prognostic stratification are still great challenges. The broad characterization of the autoantibody repertoire in SLE is…
Abstract Number: 2318 • 2016 ACR/ARHP Annual Meeting
Real World Use of the Myositis Autoantibody Panel
Jason Weiner¹, Ryan Jessee², Robert T. Keenan³, Michael Datto⁴ and Lisa Criscione-Schreiber⁵, ¹Division of Rheumatology, Duke University, Durham, NC, ²Division of Internal Medicine, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC, ⁴Division of Pathology, Duke University, Durham, NC, ⁵Division of Rheumatology, Department of Medicine, Duke University, Durham, NC
Background/Purpose: The identification of myositis specific and associated autoantibodies occurring in idiopathic inflammatory myopathies (IIMs) has improved classification and prognosis determinations. With commercial availability, these…
Abstract Number: 285 • 2016 ACR/ARHP Annual Meeting
Antibodies to Small Ubiquitin-like Modifier Activating Enzyme: Frequency and Characteristics of Antibody-Positive Patients in an Unselected Cohort
Anne Tebo¹, Troy Jaskowski² and Lisa Peterson¹, ¹Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, ²ARUP Laboratories, Salt Lake City, UT
Background/Purpose: Antibodies to small ubiquitin-like modifier activating enzyme (SAE) are associated with diagnosis of dermatomyositis (DM). The aims of this study were to establish the…
Abstract Number: 1112 • 2016 ACR/ARHP Annual Meeting
Hypoxia Modulates Neutrophil Integrin Expression, Adhesion and Trans-Endothelial Migration
Akif A. Khawaja^1,2, Charis Pericleous^3,4, Vera M. Ripoll¹, Joanna C. Porter⁵ and Ian Giles³, ¹Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ²Centre for Inflammation and Tissue Repair, Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom, ³Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom, ⁴Imperial College Vascular Sciences, National Heart and Lung Institute, Imperial College Vascular Sciences, National Heart and Lung Institute, London, United Kingdom, ⁵Centre for Inflammation and Tissue Repair, Division of Medicine, Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom
Background/Purpose: Dysregulation of neutrophil activation is important in the pathogenesis of various inflammatory and autoimmune rheumatic diseases (ARDs), including RA, SLE and APS. Neutrophils are…
Abstract Number: 2423 • 2016 ACR/ARHP Annual Meeting
Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity
Hanna Kim¹, Terrance P. O'Hanlon², Adriana Almeida de Jesus³, Yan Huang³, Ira N. Targoff^4,5, Frederick W. Miller², Raphaela Goldbach-Mansky⁶ and Lisa G. Rider², ¹NIAMS/NIH, Bethesda, MD, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: JDM is a complex autoimmune disease with an interferon (IFN) signature, with a reported correlation with disease activity. Clinical features vary among myositis-specific autoantibody…
Abstract Number: 467 • 2016 ACR/ARHP Annual Meeting
Interleukin-21-Signaling in B Cells, but Not in T Cells, Is Indispensable for Development of Collagen-Induced Arthritis in Mice
Koji Sakuraba^1,2, Kenjiro Fujimura^1,2, Hisaaki Miyahara¹ and Hisakata Yamada², ¹Clinical Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, ²Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
Background/Purpose: IL-21 is a T cell-derived cytokine whose receptor is expressed on variety of cells in immune system. IL-21was reported to be involved in the…
Abstract Number: 1208 • 2016 ACR/ARHP Annual Meeting
High-Throughput Screening Discovers Multiple Novel Autoantibodies in Rheumatoid Arthritis, Systemic Lupus, Systemic Sclerosis and Sjogrens Syndrome
Peter Schulz-Knappe¹, Hans-Dieter Zucht¹, Petra Budde¹, Heike Göhler¹, Daniel Wirtz¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Torsten Witte³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁴Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany
Background/Purpose: Diagnostic biomarkers are decision-making tools in clinical lab routine and are of growing importance for clinical management of patients. In autoimmune diseases, one important…
Abstract Number: 2424 • 2016 ACR/ARHP Annual Meeting
Novel Autoantigens for Anti- Endothelial Cell Antibodies in Pediatric Rheumatic Diseases Identified By Proteomics
Rie Karasawa¹, Mayumi Tamaki¹, Toshiko Sato¹, Kazuo Yudoh² and James Jarvis³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, ³Pediatrics, The University at Buffalo, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM), a systemic autoimmune vasculopathy, and juvenile idiopathic arthritis (JIA) are representative rheumatic diseases in children. However the pathogenesis of these diseases…
Abstract Number: 493 • 2016 ACR/ARHP Annual Meeting
The 2010 ACR/EULAR Criteria Are Not Sufficiently Accurate in the Early Identification of Autoantibody-Negative Rheumatoid Arthritis
Debbie M. Boeters¹, Cécile Gaujoux-Viala², Arnaud Constantin³ and Annette H.M. van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ³Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: The 2010-ACR/EULAR criteria were derived to classify RA earlier in time. Previous studies indeed observed that the 2010-criteria were fulfilled earlier than the 1987-criteria.…
Abstract Number: 1214 • 2016 ACR/ARHP Annual Meeting
Autoantibody Reactivities Correlated with SLE Disease Activity Identified By the SLE-key® iCHIP® Platform
Chaim Putterman¹, Pennina Safer², Keren Jakobi², Rachel Sorek², Ilana Gilkaite², Kyle Ferber³, Steve Wallace³, Amanda Harris Altice³, D. Scott Batty³ and Irun R Cohen^2,4, ¹Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray LTD, Rehovot, Israel, ³ImmunArray Inc., Richmond, VA, ⁴Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: We have developed an antigen microarray technology to study antibody profiles to elucidate and diagnose clinical states of SLE patients – the iCHIP® SLE-key®…
Abstract Number: 2634 • 2016 ACR/ARHP Annual Meeting
Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis
Ethan Grant¹, Martin Schwickart², Alex Godwood³, Rachel Moate³, Esther Song², Carlos Chavez², Marius Albulescu⁴, David Close⁴, Meina Liang², Tomas Mustelin⁵, Zhengbin Yao⁶ and Koustubh Ranade¹, ¹Translational Medicine, MedImmune, Gaithersburg, MD, ²Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD, ³MedImmune, Cambridge, United Kingdom, ⁴Clinical Development, MedImmune, Cambridge, United Kingdom, ⁵Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD, ⁶Respiratory, Inflammation and Autoimmunity iMED, MedImmune, Gaithersburg, MD
Background/Purpose: Mavrilimumab is an anti-GM-CSF receptor Ab that has recently demonstrated clinical efficacy in Phase 2 studies in rheumatoid arthritis (RA) patients. Predictive biomarkers to…
Abstract Number: 504 • 2016 ACR/ARHP Annual Meeting
Clinical Significance of Multiple Autoantibody Specificities in Rheumatoid Arthritis: The Role of Anti-Citrullinated Alpha-Enolase and Anti-Interferon Inducible Protein 16 Antibodies
Alessia Alunno¹, Onelia Bistoni¹, Federico Pratesi², Valeria Caneparo³, Fabiana Topini¹, Ilaria Puxeddu², Marco De Andrea⁴, Santo Landolfo⁴, Paola Migliorini² and Roberto Gerli¹, ¹Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ²Department of Clinical and Experimental Medicine, Clinical Immunology Unit, University of Pisa, Pisa, Italy, ³Department of Translational Medicine, Virology Unit, Novara Medical School, Novara, Italy, ⁴Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, Turin Medical School, Torino, Italy
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) auto-antibodies (auto-Abs) represent the current gold standard for the diagnosis of rheumatoid arthritis (RA). However, growing evidence suggests that a…
Abstract Number: 1562 • 2016 ACR/ARHP Annual Meeting
Interaction Between Antibodies to Paraoxonase 1 and PON1 rs662 Polymorphism: New Clues to Understand HDL Dysfunction and Oxidative Stress in Rheumatoid Arthritis
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Raquel López-Mejías³, Patricia López¹, Francisco Javier Ballina-García², Francisco Abal⁴, Miguel Angel Gonzalez-Gay^3,5 and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁴Centro de Salud Sariego, Siero, Servicio de Salud del Principado de Asturias (SESPA), Siero, Spain, ⁵School of Medicine, University of Cantabria, Santander, Spain
Background/Purpose: Traditional and non-traditional cardiovascular (CV) risk factors underlie CV disease occurrence in rheumatoid arthritis (RA). Recently, a functional impairment of HDL antioxidant capacity has…
Abstract Number: 2662 • 2016 ACR/ARHP Annual Meeting
Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome
Astrid Rasmussen¹, Donald U. Stone², Dustin Fife³, Michael Brown⁴, Keith Earley⁵, Lida Radfar⁶, C. Erick Kaufman⁷, David M. Lewis⁸, Nelson L. Rhodus⁹, Barbara M. Segal¹⁰, Daniel J Wallace¹¹, Michael Weisman¹², Swamy Venuturupalli¹³, Michael T. Brennan¹⁴, Christopher J Lessard³, Courtney G. Montgomery¹⁵, R. Hal Scofield¹⁵ and Kathy L. Sivils¹⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ²King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Pfizer Inc., Groton, CT, ⁵59th Medical Wing, US Air Force, San Antonio, TX, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁷Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ⁸Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁹Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁰Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ¹¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹³Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, ¹⁴Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: To assess the prevalence of smoking in patients with Sjögren’s syndrome (SS) and non-Sjögren’s sicca (non-SS sicca), and the association of smoking habits with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.